- KR₩36tn
- KR₩39tn
- KR₩4tn
South Korea vows more support measures over US tariffs, including for drugmakers (updated)
Brief: Celltrion Inc To Buy Back 100 Billion Won Worth Shares
Brief: Celltrion To Cancel Its Own Shares Worth 98.5 Billion Won
Brief: Shilpa Medicare Enters Into Settlement With Celltrion
Brief: Celltrion Inc To Acquire 50 Billion Won Worth Of Its Own Shares
Brief: Celltrion Submits Plan For Phase 3 Clinical Trials For Darzalex Biosimilar Ct-P44 To South Korean Regulator
Brief: U.S. FDA Approves Celltrion Inc's Omlyclo, Biosimilar To Xolair
South Korean shares end marginally higher amid mixed earnings
Brief: Celltrion To Buy Back 100 Billion Won Worth Of Own Shares
Brief: Celltrion Inc Signs 100 Billion Won Supply Contract
Brief: Celltrion Inc Has Applied To European Medicines Agency For Phase 3 Clinical Trial Of Ct-P55, Biosimilar To Novartis' Cosentyx To Treat Plaque Psoriasis
Brief: Celltrion Inc Receives Final Market Approval For Steqeyma, Used For The Treatment Of Paediatric Plaque Psoriasis, Psoriatic Arthritis, And Crohn’S Disease From The European Commission
Brief: Celltrion Inc Q2 Consolidated Operating Profit 72.5 Billion Won, Down 60.4% From Year Earlier
Brief: Celltrion Inc To Acquire 75 Billion Won Worth Of Own Shares
Brief: CelltrionShows Promising Results In Phase III Study Of Ct-P47, Biosimilar Candidate Of Roactemra In Patients With Rheumatoid Arthritis
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
Brief: Celltrion Inc Receives Market Approval From South Korea's Ministry Of Food And Drug Safety For 'Eydenzelt,' Biosimilar Of Eyelea Drug
Brief: Celltrion Q1 Consolidated Operating Profit 15.4 Billion Won, Down 91.5% From Year Earlier
Brief: Celltrion To Cancel 176.5 Billion Won Worth Of Own Shares